Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04611750 · ClinicalTrials.gov registry record · Phase 2
Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT04611750 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 53 participants.
The verdict
NCT04611750, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
Currently, there is no pharmacological intervention for mild symptomatic obstructive sleep disordered breathing (SDB) in the form of loud habitual snoring, inspiratory flow limitation (i.e. upper airway resistance syndrome), or mild sleep apnea. Here the investigators study the effect on SDB of stimulating pharyngeal muscles during sleep with AD036. The key hypothesis of the study is that AD036 is superior to placebo on self-reported and objective measures of SDB severity.
Interventions
- DRUG Placebo
- DRUG AD036
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2022-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04611750
The ClinicalTrials.gov registry entry for NCT04611750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04611750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04611750 about?
NCT04611750 is a clinical study titled "Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing". Currently, there is no pharmacological intervention for mild symptomatic obstructive sleep disordered breathing (SDB) in the form of loud habitual snoring, inspiratory flow limitation (i.e. upper airway resistance syndrome), or mild sleep apnea. Here the investigators study the effect on SDB of stim...
What is the current status of trial NCT04611750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2020-12-02. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT04611750?
The interventions under investigation include: Placebo (DRUG), AD036 (DRUG).
Who is sponsoring clinical trial NCT04611750?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.